IXICO PLC (LON:IXI) said it has won a follow-on contract worth GBP1.9mln with an existing sponsor that will use the company’s AI and neuro-imaging technology in a phase Ib/II clinical trial of a drug for Huntington’s disease (HD).
“The new award reflects and reinforces the confidence customers place in IXICO as the trusted and leading neuroimaging partner for Huntington’s disease clinical trials,” the company said.
Practically and financially, it adds to IXICO’s strong and growing order book.
By deploying its imaging biomarkers in early-phase studies, IXICO enables scientists to accelerate research and development decision making, thus maximising the value of their drug development pipelines.
The company has been working for 13 years to help find a treatment for Huntington’s, a devastating rare neurological condition with unmet medical needs.
In a statement, chief commercial officer, Lammert Albers, said: “[We are] pleased to build further momentum in our mission to support our clients in delivering data analytics in these challenging areas of rare, neurodegenerative disease.
“Our services will enable clients to measure the impact of trialled drugs with greater confidence and potentially unlock new insights into disease progression and drug development.”
